Wall Street analysts forecast that Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.64 per share in its upcoming release, pointing to a year-over-year decline of 5.9%. It is anticipated that revenues will amount to $147.08 million, exhibiting an increase of 4% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Product revenue, Net- FIRDAPSE' will reach $98.94 million. The estimate indicates a change of +18.2% from the prior-year quarter.
Analysts predict that the 'Revenues- Product revenue, Net- FYCOMPA' will reach $13.07 million. The estimate indicates a year-over-year change of -63.3%.
Analysts expect 'Revenues- Product revenue, Net- AGAMREE' to come in at $35.01 million. The estimate suggests a change of +58.8% year over year.
The average prediction of analysts places 'Revenues- Product revenue,net' at $147.01 million. The estimate indicates a change of +4% from the prior-year quarter.
View all Key Company Metrics for Catalyst here>>>Shares of Catalyst have demonstrated returns of +20.6% over the past month compared to the Zacks S&P 500 composite's +11.4% change. With a Zacks Rank #2 (Buy), CPRX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).